Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Doxecitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.55 |
| ▸ | ALB | P02768 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL2027315 | 1.00 | POLB (0.67) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL21643137 | 1.00 | POLB (0.67) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL4862620 | 0.95 | POLB (0.64) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL18149017 | 0.95 | POLB (0.64) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL23346798 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL23178 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL887491 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL10238960 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL13700553 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB | |
| Doxecitine SCHEMBL193815 | 0.95 | DNMT1 (0.66) | POLBDNMT1ADRB1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551716-A | 2' -deoxycytidine monophosphate and enzymatic synthesis method thereof | 生工生物工程（上海）股份有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-105849251-A | Nucleoside supplementation for promoting cellular function, genetic stability and regenerative applications | 加利福尼亚大学董事会 | 2016-08-10 | — | — | CN | claimed |
| CN-115125279-B | Recombinant microorganism and method for producing 2' -deoxycytidine | 苏州华赛生物工程技术有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117551716-A | 2' -deoxycytidine monophosphate and enzymatic synthesis method thereof | 生工生物工程（上海）股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117551716-A | 2' -deoxycytidine monophosphate and enzymatic synthesis method thereof | 生工生物工程（上海）股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117551716-A | 2' -deoxycytidine monophosphate and enzymatic synthesis method thereof | 生工生物工程（上海）股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20240016938-A1 | METHODS FOR INCREASING THE BIOAVAILABILITY OF NUCLEOSIDE MEDICINAL AGENTS | UCB BIOSCIENCES, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-115125279-A | Recombinant microorganism and method for producing 2' -deoxycytidine | 苏州华赛生物工程技术有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3889251-A1 | CULTURE MEDIA FOR MYCOPLASMA | Fundació Centre de Regulació Genòmica (ES) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021078935-A1 | CULTURE MEDIA FOR MYCOPLASMA | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021078938-A1 | CULTURE MEDIA FOR MYCOPLASMA | FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) | 2021-04-29 | — | — | WO | disclosed |
| US-20020192677-A1 | Nucleic acid amplification with DNA-dependent RNA polymerase activity of RNA replicases | PROMEGA CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6369207-B1 | FOR DETECTING NUCLEIC ACID ANALYTE IN A TEST SAMPLE | PROMEGA CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6090589-A | USING CHIMERIC NUCLEIC ACID INCLUDING DNA NUCLEOTIDES AND AN RNA SEQUENCE WHICH CAN BE AUTOCATALYTICALLY REPLICATED | PROMEGA CORPORATION (US) | 2000-07-18 | — | — | US | disclosed |
| CN-1045539-C | CDNA clones coding for polypepstides exhibiting human granulocyte macrophage and eosinophie cellular growth | SCHERING BIOTECH CORP (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0519053-B1 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES | PROMEGA CORP (US) | 1997-10-29 | — | — | EP | disclosed |
| CN-1106296-A | Nutritional Supplement | SANDOZ NUTRITION LTD (CH) | 1995-08-09 | — | — | CN | disclosed |
| EP-0519053-A4 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0519053-A1 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES. | PROMEGA CORP (US) | 1992-12-23 | — | — | EP | disclosed |
| WO-1992012261-A1 | NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNA POLYMERASE ACTIVITY OF RNA REPLICASES | PROMEGA CORPORATION (US) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016938-A1 | METHODS FOR INCREASING THE BIOAVAILABILITY OF NUCLEOSIDE MEDICINAL AGENTS | OAT, NME4, TK2 | ADRB1 3077/4885POLB 197/4885DNMT1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.